stockportfolio.pro
Repligen Corporation (RGEN)
Healthcare · Medical Instruments & Supplies · NasdaqGS
Repligen Corporation (RGEN) posted $738.26M in revenue for fiscal 2025 (up 16.4% year over year), at a 6.6% net margin, and has compounded revenue about 15.0%/yr over five years, per its SEC filings.
Data last refreshed June 15, 2026 from SEC filings · how we compute this
Repligen Corporation revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $104.54M | $141.24M | $194.03M | $270.25M | $366.26M | $670.53M | $801.54M | $638.76M | $634.44M | $738.26M |
| Gross profit | $57.42M | $74.19M | $107.50M | $151.15M | $209.63M | $391.25M | $455.71M | $284.84M | $274.64M | $386.25M |
| Net income | $11.68M | $28.35M | $16.62M | $21.41M | $59.93M | $128.29M | $185.96M | $41.58M | $-25.51M | $48.89M |
| Net margin | 11.2% | 20.1% | 8.6% | 7.9% | 16.4% | 19.1% | 23.2% | 6.5% | -4.0% | 6.6% |
Source: Repligen Corporation SEC filings (10-K). 17 years of history available in the interactive view.
What growth is priced into RGEN stock?
At today's market cap of $7.39B, Repligen Corporation is priced for free-cash-flow growth of about 26.5% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $93.90M from the FY ending 2025-12-31). For comparison, free cash flow actually grew 18.5%/yr over the last five fiscal years and revenue 15%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 17 years of Repligen Corporation financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track RGEN in your portfolio →
Repligen Corporation financial history by metric
Compare Repligen Corporation with peers
About Repligen Corporation
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Repligen Corporation — frequently asked questions
What is Repligen Corporation's revenue?
Repligen Corporation (RGEN) reported revenue of $738.26M for fiscal year 2025, up 16.4% from the prior year, according to its SEC filings.
Is Repligen Corporation profitable?
Yes. RGEN earned net income of $48.89M in fiscal 2025, a net margin of 6.6%.
What is RGEN's P/E ratio?
Repligen Corporation trades at a price-to-earnings ratio of about 144.0 based on the latest data in our nightly-refreshed cache.
How fast is Repligen Corporation growing?
RGEN's revenue grew at roughly 15.0% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Repligen Corporation have?
As of fiscal year 2025, RGEN carried roughly $542.21M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Repligen Corporation's gross margin?
RGEN's gross margin was 52.3% in fiscal 2025 — gross profit of $386.25M on revenue of $738.26M.
What is Repligen Corporation's market cap?
Repligen Corporation (RGEN) has a market capitalization of about $7.39B, based on the latest data in our nightly-refreshed cache.
When does Repligen Corporation's fiscal year end?
RGEN's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into RGEN stock?
At today's market cap of $7.39B, Repligen Corporation is priced for free-cash-flow growth of about 26.5% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $93.90M from the FY ending 2025-12-31). For comparison, free cash flow actually grew 18.5%/yr over the last five fiscal years and revenue 15%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Repligen Corporation's official SEC filings (10-K and 10-Q), covering 17 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.